NEW YORK, April 14, 2016 /PRNewswire/ -- Datamonitor Healthcare's comprehensive atopic dermatitis report provides a 10-year patient based sales forecast, key prescribing information based on a survey of 216 dermatologists, marketed and pipeline profiles, and a 20-year epidemiology forecast. The reports covers key marketed therapies for atopic dermatitis, as well as analysis and forecasts for Phase III pipeline products. The report provides insight into how the market for atopic dermatitis will change over the next ten years, and how prescribing will adapt following the launch of the first biologic therapy for this indication.
Datamonitor Healthcare uses a patient-based approach to size the atopic dermatitis market opportunity across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) during 2015–24. With the report you will also access results from our survey of 216 dermatologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain an insight into atopic dermatitis diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision-making, and key treatment challenges.
Why this report?
Topical agents remain the mainstay of therapy in atopic dermatitis, but key brands face generic and pipeline competition.
Dupilumab is set to address key unmet needs and its launch will inject significant growth into the atopic dermatitis market.
Significant unmet need remains for novel systemic therapies suitable for the treatment of severe refractory patients.
Datamonitor Healthcare anticipates that dupilumab, the first biologic expected to be approved for atopic dermatitis, will drive growth in the market during the 2015–24 forecast period. Datamonitor Healthcare forecasts that the atopic dermatitis market value in the US, Japan, and five major EU markets will increase from approximately $579.2m in 2015 to $2.1bn in 2024, representing a strong compound annual growth rate of 15.6%.
Topical corticosteroids remain the mainstay of atopic dermatitis treatment; however, their use is limited to 2–4 weeks due to the risk of adverse effects such as skin atrophy. In addition, steroid phobia is often the cause of poor adherence to treatment, resulting in ineffective management of the disease. Anacor Pharmaceuticals' novel phosphodiesterase 4 inhibitor, crisaborole, has the potential to meet the need for a non-steroidal topical therapy, although its future cost will play a critical role in its uptake in atopic dermatitis, which is a market dominated by low-cost topical therapies.
The development of a safe and effective systemic therapy for patients with severe refractory atopic dermatitis remains among the most prominent unmet needs in the condition. While systemic immunosuppressants, including cyclosporine and methotrexate, are often used for the management of this difficult-to-treat population, they are prescribed cautiously due to their poor side-effect profile.
Key questions our atopic dermatitis research will help you answer:
- What is the size of the atopic dermatitis market and how will this change in the future?
- How will the late-phase candidates, dupilumab and crisaborole, fit into the existing atopic dermatitis treatment algorithm?
- What do dermatologists consider to be the greatest unmet needs in atopic dermatitis?
- Will the late-phase candidates address these unmet needs?
Read the full report: http://www.reportlinker.com/p03714634-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atopic-dermatitis-an-increased-focus-on-development-of-targeted-therapies-will-address-key-unmet-needs---marketed-drugs-pipeline-forecast-treatment-and-epidemiology-300251024.html